Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses EDITORIAL COMMENT

被引：0
|
作者：
Smoragiewicz, Martin [1 ]
Emmenegger, Urban [1 ]
机构：
[1] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF UROLOGY | 2021年 / 205卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1370 / 1370
页数：1
相关论文
共 50 条
  • [11] KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
    Gratzke, Christian
    Kwiatkowski, Mariusz
    Giorgi, Ugo De
    Martins da Trindade, Karine
    De Santis, Maria
    Armstrong, Andrew J.
    Niu, Cuizhen
    Liu, Yingjie
    Poehlein, Christian Heinrich
    FUTURE ONCOLOGY, 2022, 18 (37) : 4079 - 4087
  • [12] ENZALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR ANTIANDROGEN THERAPY: POST HOC ANALYSIS OF ARCHES
    Shore, Neal D.
    Iguchi, Taro
    Villers, Arnauld
    Alcaraz, Antonio
    Gomez-Veiga, Francisco
    Stenzl, Arnulf
    Azad, Arun A.
    Alekseev, Boris
    Petrylak, Daniel P.
    Szmulewitz, Russell Z.
    Holzbeierlein, Jeffrey
    Rosbrook, Brad
    Zohren, Fabian
    Haas, Gabriel P.
    Gourgioti, Georgia
    El-Chaar, Nader N.
    Armstrong, Andrew J.
    JOURNAL OF UROLOGY, 2021, 206 : E585 - E585
  • [13] HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES
    Sharifi, Nima
    Azad, Arun A.
    Patel, Mona
    Hearn, Jason W. D.
    Wozniak, Michele
    Zohren, Fabian
    Sugg, Jennifer
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    CELL REPORTS MEDICINE, 2024, 5 (08)
  • [14] Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
    Iguchi, Taro
    Kimura, Go
    Fukasawa, Satoshi
    Suzuki, Hiroyoshi
    Uemura, Hiroji
    Nishimura, Kazuo
    Matsumoto, Hiroaki
    Yokomizo, Akira
    Armstrong, Andrew J.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Kunieda, Futoshi
    Stenzl, Arnulf
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (07) : 765 - 773
  • [15] Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups
    Hong, Jun Hyuk
    Stenzl, Arnulf
    Szmulewitz, Russell Z.
    Petrylak, Daniel
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris Y.
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Baron, Benoit
    Haas, Gabriel P.
    Morlock, Robert
    Ramaswamy, Krishnan
    Armstrong, Andrew J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 102 - 103
  • [16] ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
    Stenzl, A.
    Szmulewitz, R. Z.
    Petrylak, D. P.
    Holzbeierlein, J.
    Villers, A.
    Azad, A. A.
    Alcaraz, A.
    Alekseev, B. Y.
    Iguchi, T.
    Shore, N. D.
    Rosbrook, B.
    Baron, B.
    Haas, G. P.
    Morlock, R.
    Ramaswamy, K.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 332 - +
  • [17] OVERALL SURVIVAL IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE OR PLACEBO PLUS ANDROGEN DEPRIVATION THERAPY WHO HAD PRIOR LOCAL THERAPY: POST HOC ANALYSIS OF THE PHASE 3 ARCHES TRIAL
    Iguchi, Taro
    Villers, Arnauld
    Shore, Neal D.
    Azad, Arun A.
    Szmulewitz, Russell Z.
    Holzbeierlein, Jeffrey
    Alcaraz, Antonio
    Alekseev, Boris
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Lee, Ho-Jin
    Haas, Gabriel P.
    Armstrong, Andrew J.
    Stenzl, Arnulf
    JOURNAL OF UROLOGY, 2022, 207 (05): : E455 - E455
  • [18] Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
    Sweeney, Christopher J.
    Martin, Andrew J.
    Stockler, Martin R.
    Begbie, Stephen
    Chi, Kim N.
    Chowdhury, Simon
    Coskinas, Xanthi
    Frydenberg, Mark
    Hague, Wendy E.
    Horvath, Lisa G.
    Joshua, Anthony M.
    Lawrence, Nicola J.
    Marx, Gavin M.
    McCaffrey, John
    McDermott, Ray
    McJannett, Margaret
    North, Scott A.
    Parnis, Francis
    Parulekar, Wendy
    Pook, David W.
    Reaume, M. Neil
    Sandhu, Shahneen K.
    Tan, Alvin
    Tan, Thean Hsiang
    Thomson, Alastair
    Tu, Emily
    Vera-Badillo, Francisco
    Williams, Scott G.
    Yip, Sonia
    Zhang, Alison Y.
    Zielinski, Robert R.
    Davis, Ian D.
    EUROPEAN UROLOGY, 2021, 80 (03) : 275 - 279
  • [19] Efficacy and Safety of Enzalutamide Plus ADT Versus Placebo Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer: The Arches Trial
    Stenzl, A.
    Azad, A.
    Krivoshik, A.
    Baron, B.
    Hirmand, M.
    Armstrong, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 73 - 73
  • [20] Post hoc analysis of East Asian subpopulation in arches, a phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC)
    Iguchi, Taro
    Pu, Yeong-Shiau
    Kimura, Go
    Byun, Seok-Soo
    Ha, Hong Koo
    Hong, Jun Hyuk
    Li, Jian-Ri
    Sugg, Jennifer
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 96 - 97
12345